Mary E. Rinella, MD is a Professor of Medicine in the Gastroenterology, Hepatology and Nutrition section at the University of Chicago since January 2021. She is the director of the Metabolic and Fatty Liver Program as well as Director of Clinical trials for the section.
She has held several national societal leadership roles, including on the Governing Board of the American Association for the Study of Liver Disease (AASLD). She was lead author of the 2023 AASLD Clinical Practice Guidance on the diagnosis and management of NAFLD, now MASLD. She recently led a multi-society global effort to revise the nomenclature of NAFLD and served as Chair of the AASLD Steatotic Liver Disease (SLD) task force, charged with increasing disease awareness, disseminating best practice, developing a national strategy and fortifying global collaborations to improve care and outcomes of patients with SLD.
The metabolic (fatty liver) liver clinic provides multidisciplinary care to patients in collaboration with an obesity medicine specialist as well as a dietician to provide individualized, patient-centered care. Here patients have access to the latest approved therapies as well as clinical trials with emerging therapies. While her research and clinical focus is metabolic liver disease, she has significant expertise and interest in cholestatic liver disease, including PBC and PSC and autoimmune liver disease, as well as in complications of cirrhosis and portal hypertension.
Development and validation of a model using routine clinical features to improve diabetes diagnosis.
Development and validation of a model using routine clinical features to improve diabetes diagnosis. J Endocr Soc. 2026 Nov; 10(11):bvag225.
PMID: 42898234
International expert panel review for the use of resmetirom and semaglutide in the management of MASH-related fibrosis: clinical practice update.
International expert panel review for the use of resmetirom and semaglutide in the management of MASH-related fibrosis: clinical practice update. Gut. 2026 Sep 11.
PMID: 42728029
Review Article: Fibrosis Reversal in Metabolic Dysfunction-Associated Steatohepatitis-The Promise of Emerging Therapeutics.
Review Article: Fibrosis Reversal in Metabolic Dysfunction-Associated Steatohepatitis-The Promise of Emerging Therapeutics. Aliment Pharmacol Ther. 2026 Nov; 64(9):1184-1196.
PMID: 42608656
Author Correction: The dynamic spectrum of steatotic liver disease: the global perspective.
Author Correction: The dynamic spectrum of steatotic liver disease: the global perspective. Nat Rev Gastroenterol Hepatol. 2026 Aug 14.
PMID: 42601399
The dynamic spectrum of steatotic liver disease: the global perspective.
The dynamic spectrum of steatotic liver disease: the global perspective. Nat Rev Gastroenterol Hepatol. 2026 Nov; 23(11):812-829.
PMID: 42567912
The economic burden of MASH: comparison of healthcare resource utilization and costs in patients with probable MASH, without MASH, and with diagnosed MASH.
The economic burden of MASH: comparison of healthcare resource utilization and costs in patients with probable MASH, without MASH, and with diagnosed MASH. Expert Rev Pharmacoecon Outcomes Res. 2026 Jul 16; 1-14.
PMID: 42377008
The Transitional Liver Clinic: Study protocol for a stepped-wedge cluster randomized trial.
The Transitional Liver Clinic: Study protocol for a stepped-wedge cluster randomized trial. Hepatol Commun. 2026 Jul 01; 10(7).
PMID: 42319136
Accuracy of the FIB-4 and LiverRisk score for use in primary risk assessment for liver fibrosis, and variation by age.
Accuracy of the FIB-4 and LiverRisk score for use in primary risk assessment for liver fibrosis, and variation by age. Dig Liver Dis. 2026 07; 58(7):935-942.
PMID: 42303324
Clinical Outcomes and Non-Invasive Testing in Metabolic Dysfunction-Associated Steatohepatitis With Cirrhosis: A Systematic Review.
Clinical Outcomes and Non-Invasive Testing in Metabolic Dysfunction-Associated Steatohepatitis With Cirrhosis: A Systematic Review. Liver Int. 2026 05; 46(5):e70608.
PMID: 41902599
Refining HEPAmet for Treatment Eligibility in Metabolic Dysfunction-Associated Steatotic Liver Disease: External Validation and Guardrail to Exclude Cirrhosis, Limit Early Disease.
Refining HEPAmet for Treatment Eligibility in Metabolic Dysfunction-Associated Steatotic Liver Disease: External Validation and Guardrail to Exclude Cirrhosis, Limit Early Disease. Clin Gastroenterol Hepatol. 2026 Apr 12.
PMID: 41974245